Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

(2021) Thomas Bieber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2021) Kristian Reich et al.   LANCET

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

(2021) Emma Guttman-Yassky et al.   LANCET

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

(2020) E.L. Simpson et al.   BRITISH JOURNAL OF DERMATOLOGY

Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis

(2020) Pablo Olivera et al.   GASTROENTEROLOGY

Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis

(2020) William J. Sandborn et al.   GASTROENTEROLOGY

ROLE OF PHOTOTHERAPY IN THE ERA OF BIOLOGICS

(2020) Angeli Eloise E. Torres et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Thromboembolism and Janus Kinase Inhibitors

(2020) Fowzia Ibrahim et al.   DRUG SAFETY

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Eric L Simpson et al.   LANCET

Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19

(2020) Sarah C.J. Jorgensen et al.   PHARMACOTHERAPY

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

(2020) Jonathan I. Silverberg et al.   JAMA Dermatology

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

(2020) Kristian Reich et al.   JAMA Dermatology

Inhibition of IL-13: A New Pathway for Atopic Dermatitis

(2020) Kayadri Ratnarajah et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials

(2019) Chengfeng Qiu et al.   Lipids in Health and Disease

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN 002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

(2019) R. Bissonnette et al.   BRITISH JOURNAL OF DERMATOLOGY

Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data

(2019) L. E. M. de Wijs et al.   BRITISH JOURNAL OF DERMATOLOGY

Real‐world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records

(2019) Candice Wang et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial

(2019) Roy Fleischmann et al.   Arthritis & Rheumatology

Recent Therapeutic Advances in Pruritus Management for Atopic Dermatitis Patients: A Welcome Addition of Asivatrep to Our Arsenal of Future Topical Treatments

(2019) Sabrina Bartolucci et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinib

(2019) Pamela Anjara et al.   CLINICAL RHEUMATOLOGY

The IL ‐13– OVOL 1– FLG axis in atopic dermatitis

(2019) Kazuhisa Furue et al.   IMMUNOLOGY

Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial

(2019) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

(2019) Melinda J. Gooderham et al.   JAMA Dermatology

Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States

(2019) Hasan Khosravi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

(2019) Désirée van der Heijde et al.   LANCET

Emerging Topical and Systemic JAK Inhibitors in Dermatology

(2019) Farzan Solimani et al.   Frontiers in Immunology

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies

(2018) Peter C Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study

(2018) G.J. Schmieder et al.   BRITISH JOURNAL OF DERMATOLOGY

Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study

(2018) Kenji Kabashima et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

(2018) Andreas Wollenberg et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

(2018) Emma Guttman-Yassky et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

(2018) Eric L. Simpson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies

(2017) Patrick M. Brunner et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis

(2017) Robert Wolk et al.   Journal of Clinical Lipidology

The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association

(2017) Aaron M. Drucker et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

(2017) Dafna Gladman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Malignancy and Janus Kinase Inhibition

(2017) Padmapriya Sivaraman et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma

(2017) Dirk Smith et al.   PLoS Genetics

Review of Systemic Treatment Options for Adult Atopic Dermatitis

(2016) Melinda Gooderham et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

(2016) Kim A. Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Atopic dermatitis

(2016) Stephan Weidinger et al.   LANCET

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

(2016) Eric L. Simpson et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Comprehensive Review of the Treatment of Atopic Eczema

(2016) Ji Hyun Lee et al.   Allergy Asthma & Immunology Research

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling

(2015) Wataru Amano et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Guidelines of care for the management of atopic dermatitis

(2014) Robert Sidbury et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Epidemiology of atopic dermatitis: a review

(2012) Sigrid Payne DaVeiga   ALLERGY AND ASTHMA PROCEEDINGS

Recognizing and Managing Eczematous Id Reactions to Molluscum Contagiosum Virus in Children: FIGURE 1

(2012) Elena Netchiporouk et al.   PEDIATRICS

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE